362 related articles for article (PubMed ID: 20979781)
1. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
[TBL] [Abstract][Full Text] [Related]
2. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1155-8. PubMed ID: 22883000
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of bone mineral density in Iranian HIV/AIDS patients.
Badie BM; Soori T; Kheirandish P; Izadyar S; SeyedAlinagh S; Foroughi M; Rostamian A; Mohraz M
Acta Med Iran; 2011; 49(7):460-7. PubMed ID: 21960080
[TBL] [Abstract][Full Text] [Related]
4. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
Brown TT; Ruppe MD; Kassner R; Kumar P; Kehoe T; Dobs AS; Timpone J
J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
[TBL] [Abstract][Full Text] [Related]
5. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
Fernández-Rivera J; García R; Lozano F; Macías J; García-García JA; Mira JA; Corzo JE; Gómez-Mateos J; Rueda A; Sánchez-Burson J; Pineda JA
HIV Clin Trials; 2003; 4(5):337-46. PubMed ID: 14583850
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
[TBL] [Abstract][Full Text] [Related]
7. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
Rey D; Treger M; Sibilia J; Priester M; Bernard-Henry C; Cheneau C; Javier RM
Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
[TBL] [Abstract][Full Text] [Related]
9. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
Cazanave C; Dupon M; Lavignolle-Aurillac V; Barthe N; Lawson-Ayayi S; Mehsen N; Mercié P; Morlat P; Thiébaut R; Dabis F;
AIDS; 2008 Jan; 22(3):395-402. PubMed ID: 18195566
[TBL] [Abstract][Full Text] [Related]
10. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Mannazzu M; Falchi A; Sanna D; Mura MS; Madeddu G
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):290-301. PubMed ID: 18596668
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
Mora S; Sala N; Bricalli D; Zuin G; Chiumello G; Viganò A
AIDS; 2001 Sep; 15(14):1823-9. PubMed ID: 11579244
[TBL] [Abstract][Full Text] [Related]
12. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
[TBL] [Abstract][Full Text] [Related]
13. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
[TBL] [Abstract][Full Text] [Related]
14. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
Rivas P; Górgolas M; García-Delgado R; Díaz-Curiel M; Goyenechea A; Fernández-Guerrero ML
HIV Med; 2008 Feb; 9(2):89-95. PubMed ID: 18093130
[TBL] [Abstract][Full Text] [Related]
15. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
[TBL] [Abstract][Full Text] [Related]
16. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
17. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
18. BMD is reduced in HIV-infected men irrespective of treatment.
Amiel C; Ostertag A; Slama L; Baudoin C; N'Guyen T; Lajeunie E; Neit-Ngeilh L; Rozenbaum W; De Vernejoul MC
J Bone Miner Res; 2004 Mar; 19(3):402-9. PubMed ID: 15040828
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents.
Schtscherbyna A; Pinheiro MF; Mendonça LM; Gouveia C; Luiz RR; Machado ES; Farias ML
Int J Infect Dis; 2012 Dec; 16(12):e872-8. PubMed ID: 23031418
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2006 Aug; 65(2):191-7. PubMed ID: 16886959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
